文献速递外周动脉疾病

股总动脉内膜剥脱术联合流入道及流出道腔内治疗在慢性肢体威胁性缺血中的中期结果

Midterm Outcomes of Common Femoral Endarterectomy Combined with Inflow and Outflow Endovascular Treatment for Chronic Limb Threatening Ischaemia.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-03-27

前瞻性研究纳入2015年至2017年因多节段病变导致慢性肢体威胁性缺血、首次接受一期股总动脉内膜剥脱术联合流入道和/或流出道腔内血运重建的患者,按腔内治疗区域分三组,总体技术成功率98%,围术期并发症率14%、死亡率2%,组3在24个月原发通畅率显著较低但二期通畅率改善,病变长度、CTO、PACSS 4级、不完全血运重建和血脂异常是原发通畅丧失的独立预测因素。

要点

  • 股总动脉内膜剥脱术联合流入道和/或流出道腔内治疗安全,通畅率可接受,但需二次干预。
  • 联合流入道及流出道腔内治疗组24个月原发通畅率较低,但二期通畅率改善。
  • 病变长度、CTO、PACSS 4级、不完全血运重建和血脂异常是原发通畅丧失的独立预测因素。

核心结论

  • 股总动脉内膜剥脱术联合流入道及流出道腔内血运重建在慢性肢体威胁性缺血患者中安全,通畅率可接受,尽管需要二次干预。
  • 血脂异常、病变长度、CTO、PACSS 4级和不完全血运重建是原发通畅丧失的独立预测因素。
  • 本研究分析支持根据患者风险和肢体威胁程度分期手术的建议。

研究设计与样本

  • 前瞻性研究,纳入2015年1月至2017年5月首次接受计划性一期股总动脉内膜剥脱术联合流入道和/或流出道腔内血运重建以保肢的慢性肢体威胁性缺血多节段病变患者。
  • 按腔内治疗区域分三组:组1流入道(n=60)、组2流出道(n=46)、组3联合流入道和流出道(n=53);股总动脉内膜剥脱术为所有病例的固定步骤。

主要发现

  • 总体技术成功率为98%。
  • 围术期并发症率为14%,死亡率为2%。
  • 组3在24个月原发通畅率显著较低(53.9% ± 7.1%;p < .001),但二期通畅率改善(94.0% ± 3.4%)。
  • Cox回归多变量分析显示,病变长度(HR 1.10,95%CI 1.06-1.14;p < .001)、CTO(HR 0.50,95%CI 0.25-0.98;p = .046)、PACSS 4级(HR 2.44,95%CI 1.27-4.68;p = .008)、不完全血运重建(HR 3.32,95%CI 1.64-6.73;p = .001)和血脂异常(HR 0.50,95%CI 0.27-0.93;p = .031)是原发通畅丧失的唯一显著独立预测因素。

临床怎么用

  • 对于慢性肢体威胁性缺血多节段病变患者,可考虑股总动脉内膜剥脱术联合流入道和/或流出道腔内血运重建,需权衡二次干预风险。
  • 应关注病变长度、CTO、PACSS 4级、不完全血运重建和血脂异常等原发通畅丧失预测因素,个体化制定手术策略。
  • 根据患者风险和肢体威胁程度分期手术可能获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess mid term outcomes of common femoral endarterectomy combined with an inflow and outflow endovascular revascularisation procedure in patients with chronic limb threatening ischaemia (CLTI). METHODS: This was a prospective study. All patients who, for the first time, underwent planned one stage hybrid common femoral artery (CFA) endarterectomy combined with an inflow and/or outflow endovascular revascularisation procedure to achieve limb salvage in patients with CLTI due to multilevel disease were included between January 2015 and May 2017. Demographics, and clinical and lesion characteristics for each patient were reported. The primary outcome was primary patency. Secondary outcomes were technical success, peri-operative morbidity and mortality, assisted primary patency, secondary patency, clinically driven target lesion revascularisation and amputation free survival. RESULTS: Three groups were created according to the endovascular treatment zone: group 1 (inflow, n = 60); group 2 (outflow, n = 46); and group 3 (combined inflow and outflow, n = 53). CFA endarterectomy was a fixed step in all cases. The overall technical success was 98%. The peri-operative complication rate was 14% and the mortality rate was 2%. Patients in group 3 demonstrated a significantly lower primary patency rate (53.9% ± 7.1%; p < .001) at 24 months but improved secondary patency rate of (94.0% ± 3.4%). Based on the outcomes of the Cox regression multivariable analysis, lesion length (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.06-1.14; p < .001), chronic total occlusion (CTO) (HR 0.50, 95% CI 0.25-0.98; p = .046), peripheral artery calcium scoring system (PACSS) grade 4 (HR 2.44, 95% CI 1.27-4.68; p = .008), incomplete revascularisation (HR 3.32, 95% CI 1.64-6.73; p = .001), and dyslipidaemia (HR 0.50, 95% CI 0.27-0.93; p = .031) were the only significant independent predictors of loss of primary patency. CONCLUSION: Common femoral endarterectomy combined with an inflow and outflow endovascular revascularisation procedure in patients with CLTI is safe, with acceptable patency rates, despite the need for secondary interventions. Dyslipidaemia, lesion length, CTO, PACSS grade 4, and incomplete revascularisation are independent predictors of primary patency loss. The current study analysis supports the recommendation to stage the procedure based on patient risk and degree of limb threat.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Elbadawy A, Ali H, Saleh M, et al. Midterm Outcomes of Common Femoral Endarterectomy Combined with Inflow and Outflow Endovascular Treatment for Chronic Limb Threatening Ischaemia. Eur J Vasc Endovasc Surg. 2020. PMID: 32224037. doi:10.1016/j.ejvs.2020.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。